




RealRate

PHARMACEUTICAL 2022

AGILE THERAPEUTICS INC
Rank 448 of 475

Agile[®]
THERAPEUTICS



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 208% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 502% points.

The company's Economic Capital Ratio, given in the ranking table, is -847%, being 571% points below the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 23,925 |
| Cost of Goods Sold | 10,718 |
| Intangible Assets | 0 |
| Liabilities, Current | 29,278 |
| Liabilities, Non-Current | 784 |
| Other Assets | 2,961 |
| Other Compr. Net Income | -3.0 |
| Other Expenses | 43,444 |
| Other Liabilities | 0 |
| Other Net Income | -3,889 |
| Property and Equipment | 12,447 |
| Research and Development | 6,246 |
| Revenues | 4,101 |
| Selling, General and Administrative Expense | 14,698 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 39,333 |
| Liabilities | 30,062 |
| Expenses | 75,106 |
| Stockholders Equity | 9,271 |
| Net Income | -74,894 |
| Comprehensive Net Income | -74,896 |
| Economic Capital Ratio | -847% |